Characteristics of patients, disease, and transplantation procedures
| Variable . | Value . |
|---|---|
| Total | 98 |
| Male | 52 (53) |
| Age | |
| 10 y or younger | 38 (39) |
| 11-20 y | 43 (44) |
| Older than 20 y | 17 (17) |
| Bone marrow status prior to transplantation | |
| Aplastic anemia | 75 (77) |
| MDS | 14 (14) |
| AML | 7 (7) |
| Unknown | 2 (2) |
| Complementation group | |
| A | 37 (38) |
| C | 12 (12) |
| D1 | 1 (1) |
| D2 | 2 (2) |
| G | 4 (4) |
| Not determined | 42 (43) |
| DEB mosaicism | |
| Absent | 34 (35) |
| Present | 45 (46) |
| Not determined | 19 (19) |
| DEB sensitivity, median (range) | 9.1 (0.5-23.9) |
| No. of prior blood transfusions | |
| None | 5 (5) |
| 1-20 | 35 (36) |
| More than 20 | 24 (24) |
| Unknown | 34 (35) |
| Therapy prior to transplantation | |
| None | 19 (19) |
| Androgens ± other including steroids | 54 (55) |
| Steroids ± other (without androgens) | 11 (11) |
| Unknown | 14 (14) |
| Year of transplantation | |
| 1990-1998 | 51 (52) |
| 1999-2003 | 47 (48) |
| Conditioning regimen* | |
| Nonfludarabine regimens | 52 (53) |
| TLI + cyclophosphamide | 2 (4) |
| TAI + cyclophosphamide + ATG | 6 (12) |
| TLI + busulfan ± ATG | 1 (1) |
| TBI + cyclophosphamide ± ATG† | 43 (83) |
| Fludarabine-containing regimens | 46 (47) |
| Cyclophosphamide + ATG | 1 (2) |
| Cyclophosphamide + busulfan + ATG | 1 (2) |
| TAI + cyclophosphamide + ATG | 1 (2) |
| TBI + cyclophosphamide ± ATG‡ | 43 (93) |
| GVHD prophylaxis | |
| Cyclosporine ± other | 16 (16) |
| Cyclosporine + methotrexate ± other | 8 (8) |
| T-cell depletion + other | 70 (71) |
| Tacrolimus ± other | 2 (2) |
| Unknown | 2 (2) |
| Donor-recipient CMV status | |
| Both donor, recipient negative | 45 (46) |
| Donor positive/recipient negative | 20 (20) |
| Donor negative/recipient positive | 24 (24) |
| Donor positive/recipient positive | 9 (9) |
| Donor-recipient sex match | |
| Female donor to male recipient | 22 (22) |
| Other | 76 (78) |
| Donor-recipient HLA match | |
| Matched | 76 (78) |
| One-antigen mismatched | 22 (22) |
| Variable . | Value . |
|---|---|
| Total | 98 |
| Male | 52 (53) |
| Age | |
| 10 y or younger | 38 (39) |
| 11-20 y | 43 (44) |
| Older than 20 y | 17 (17) |
| Bone marrow status prior to transplantation | |
| Aplastic anemia | 75 (77) |
| MDS | 14 (14) |
| AML | 7 (7) |
| Unknown | 2 (2) |
| Complementation group | |
| A | 37 (38) |
| C | 12 (12) |
| D1 | 1 (1) |
| D2 | 2 (2) |
| G | 4 (4) |
| Not determined | 42 (43) |
| DEB mosaicism | |
| Absent | 34 (35) |
| Present | 45 (46) |
| Not determined | 19 (19) |
| DEB sensitivity, median (range) | 9.1 (0.5-23.9) |
| No. of prior blood transfusions | |
| None | 5 (5) |
| 1-20 | 35 (36) |
| More than 20 | 24 (24) |
| Unknown | 34 (35) |
| Therapy prior to transplantation | |
| None | 19 (19) |
| Androgens ± other including steroids | 54 (55) |
| Steroids ± other (without androgens) | 11 (11) |
| Unknown | 14 (14) |
| Year of transplantation | |
| 1990-1998 | 51 (52) |
| 1999-2003 | 47 (48) |
| Conditioning regimen* | |
| Nonfludarabine regimens | 52 (53) |
| TLI + cyclophosphamide | 2 (4) |
| TAI + cyclophosphamide + ATG | 6 (12) |
| TLI + busulfan ± ATG | 1 (1) |
| TBI + cyclophosphamide ± ATG† | 43 (83) |
| Fludarabine-containing regimens | 46 (47) |
| Cyclophosphamide + ATG | 1 (2) |
| Cyclophosphamide + busulfan + ATG | 1 (2) |
| TAI + cyclophosphamide + ATG | 1 (2) |
| TBI + cyclophosphamide ± ATG‡ | 43 (93) |
| GVHD prophylaxis | |
| Cyclosporine ± other | 16 (16) |
| Cyclosporine + methotrexate ± other | 8 (8) |
| T-cell depletion + other | 70 (71) |
| Tacrolimus ± other | 2 (2) |
| Unknown | 2 (2) |
| Donor-recipient CMV status | |
| Both donor, recipient negative | 45 (46) |
| Donor positive/recipient negative | 20 (20) |
| Donor negative/recipient positive | 24 (24) |
| Donor positive/recipient positive | 9 (9) |
| Donor-recipient sex match | |
| Female donor to male recipient | 22 (22) |
| Other | 76 (78) |
| Donor-recipient HLA match | |
| Matched | 76 (78) |
| One-antigen mismatched | 22 (22) |
Values in table represent number of patients (%) unless otherwise indicated. ± indicates with or without; TLI, total lymphoid irradiation; TAI, total abdominal radiation; ATG, antithymocyte globulin.
Fludarabine was used exclusively after 1998.
TBI doses: 200 cGy, n = 1; 300 cGy, n = 1; 400 cGy, n = 8; 450 cGy, n = 21; 500 cGy, n = 1; and 600 cGy, n = 11.
TBI dose: 450 cGy, n = 43.